Tolerability/safety of intranasal AZD8848 in healthy male volunteers and seasonal allergic rhinitis male patients out of season - SAD
Study identifier:D0540C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Double Blind, Placebo Controlled, Randomised, First Time In Man. Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of AZD8848 Administered Intranasally to Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out Of Season
Medical condition
Healthy, Allergic Rhinitis
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD8848, Placebo
Sex
Male
Actual Enrollment
130
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Jan 2008
Primary Completion Date: 01 May 2008
Study Completion Date: 01 Apr 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Aug 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD8848 Concentrate for nasal spray,solution 60 mg/g |
| Placebo Comparator: 2 | - |
Contacts
Investigators
Principal Investigator
Edward Högestätt
Department of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine on University Hospital Lund, Sweden
